226 related articles for article (PubMed ID: 27905161)
1. The impact of co-morbidity burden on appropriate implantable cardioverter defibrillator therapy and all-cause mortality: insight from Danish nationwide clinical registers.
Ruwald AC; Vinther M; Gislason GH; Johansen JB; Nielsen JC; Petersen HH; Riahi S; Jons C
Eur J Heart Fail; 2017 Mar; 19(3):377-386. PubMed ID: 27905161
[TBL] [Abstract][Full Text] [Related]
2. Clinical outcome in patients with implantable cardioverter-defibrillator and cancer: a nationwide study.
Christensen AM; Bjerre J; Schou M; Jons C; Vinther M; Gislason GH; Johansen JB; Nielsen JC; Petersen HH; Riahi S; Ruwald AC
Europace; 2019 Mar; 21(3):465-474. PubMed ID: 30535192
[TBL] [Abstract][Full Text] [Related]
3. Risk of subsequent ventricular arrhythmia is higher in primary prevention patients with implantable cardioverter defibrillator than in secondary prevention patients.
Zhou Y; Zhao S; Chen K; Hua W; Su Y; Chen S; Liang Z; Xu W; Zhang S
BMC Cardiovasc Disord; 2019 Oct; 19(1):230. PubMed ID: 31638918
[TBL] [Abstract][Full Text] [Related]
4. Incidence of appropriate implantable cardioverter-defibrillator therapy and mortality after implantable cardioverter-defibrillator generator replacement: results from a real-world nationwide cohort.
Ruwald MH; Ruwald AC; Johansen JB; Gislason G; Nielsen JC; Philbert B; Riahi S; Vinther M; Lindhardt TB
Europace; 2019 Aug; 21(8):1211-1219. PubMed ID: 31329849
[TBL] [Abstract][Full Text] [Related]
5. Importance of beta-blocker dose in prevention of ventricular tachyarrhythmias, heart failure hospitalizations, and death in primary prevention implantable cardioverter-defibrillator recipients: a Danish nationwide cohort study.
Ruwald AC; Gislason GH; Vinther M; Johansen JB; Nielsen JC; Philbert BT; Torp-Pedersen C; Riahi S; Jøns C
Europace; 2018 Sep; 20(FI2):f217-f224. PubMed ID: 29684191
[TBL] [Abstract][Full Text] [Related]
6. Thirty-year trends in heart failure hospitalization and mortality rates and the prognostic impact of co-morbidity: a Danish nationwide cohort study.
Schmidt M; Ulrichsen SP; Pedersen L; Bøtker HE; Sørensen HT
Eur J Heart Fail; 2016 May; 18(5):490-9. PubMed ID: 26868921
[TBL] [Abstract][Full Text] [Related]
7. Sex difference in appropriate shocks but not mortality during long-term follow-up in patients with implantable cardioverter-defibrillators.
Seegers J; Conen D; Jung K; Bergau L; Dorenkamp M; Lüthje L; Sohns C; Sossalla ST; Fischer TH; Hasenfuss G; Friede T; Zabel M
Europace; 2016 Aug; 18(8):1194-202. PubMed ID: 26622054
[TBL] [Abstract][Full Text] [Related]
8. Association Between Comorbidities and Outcomes in Heart Failure Patients With and Without an Implantable Cardioverter-Defibrillator for Primary Prevention.
Khazanie P; Hellkamp AS; Fonarow GC; Bhatt DL; Masoudi FA; Anstrom KJ; Heidenreich PA; Yancy CW; Curtis LH; Hernandez AF; Peterson ED; Al-Khatib SM
J Am Heart Assoc; 2015 Aug; 4(8):e002061. PubMed ID: 26251283
[TBL] [Abstract][Full Text] [Related]
9. Mortality and appropriate and inappropriate therapy in patients with ischaemic heart disease and implanted cardioverter-defibrillators for primary prevention: data from the Danish ICD Register.
Weeke P; Johansen JB; Jørgensen OD; Nielsen JC; Møller M; Videbæk R; Højgaard MV; Riahi S; Jacobsen PK
Europace; 2013 Aug; 15(8):1150-7. PubMed ID: 23407630
[TBL] [Abstract][Full Text] [Related]
10. Incidence of and predictors for appropriate implantable cardioverter-defibrillator therapy in patients with a secondary preventive implantable cardioverter-defibrillator indication.
Schaer B; Kühne M; Reichlin T; Osswald S; Sticherling C
Europace; 2016 Feb; 18(2):227-31. PubMed ID: 26063686
[TBL] [Abstract][Full Text] [Related]
11. Performance of the subcutaneous implantable cardioverter-defibrillator in patients with a primary prevention indication with and without a reduced ejection fraction versus patients with a secondary prevention indication.
Boersma LV; Barr CS; Burke MC; Leon AR; Theuns DA; Herre JM; Weiss R; Kremers MS; Neuzil P; Husby MP; Carter N; Stivland TM; Gold MR;
Heart Rhythm; 2017 Mar; 14(3):367-375. PubMed ID: 27890798
[TBL] [Abstract][Full Text] [Related]
12. The effect of implantable cardioverter-defibrillator in patients with diabetes and non-ischaemic systolic heart failure.
Rørth R; Thune JJ; Nielsen JC; Haarbo J; Videbæk L; Korup E; Signorovitch J; Bruun NE; Eiskjær H; Hassager C; Svendsen JH; Høfsten DE; Torp-Pedersen C; Pehrson S; Køber L; Kristensen SL
Europace; 2019 Aug; 21(8):1203-1210. PubMed ID: 31323662
[TBL] [Abstract][Full Text] [Related]
13. Primary prevention implantable cardioverter-defibrillator and cardiac resynchronization therapy-defibrillator in elderly patients: results of a Spanish multicentre study.
Expósito V; Rodríguez-Mañero M; González-Enríquez S; Arias MA; Sánchez-Gómez JM; Andrés La Huerta A; Bertomeu-González V; Arce-León Á; Barrio-López MT; Arguedas-Jiménez H; Seara JG; Rodriguez-Entem F
Europace; 2016 Aug; 18(8):1203-10. PubMed ID: 26566939
[TBL] [Abstract][Full Text] [Related]
14. Thirteen-year nationwide trends in use of implantable cardioverter-defibrillators and subsequent long-term survival.
Schmidt M; Pedersen SB; Farkas DK; Hjortshøj SP; Bøtker HE; Nielsen JC; Sørensen HT
Heart Rhythm; 2015 Sep; 12(9):2018-27. PubMed ID: 25937527
[TBL] [Abstract][Full Text] [Related]
15. Real world effectiveness of primary implantable cardioverter defibrillators implanted during hospital admissions for exacerbation of heart failure or other acute co-morbidities: cohort study of older patients with heart failure.
Chen CY; Stevenson LW; Stewart GC; Bhatt DL; Desai M; Seeger JD; Williams L; Jalbert JJ; Setoguchi S
BMJ; 2015 Jul; 351():h3529. PubMed ID: 26174233
[TBL] [Abstract][Full Text] [Related]
16. Long-term morbidity and mortality after implantable cardioverter-defibrillator implantation with procedural complication: A report from the National Cardiovascular Data Registry.
Kipp R; Hsu JC; Freeman J; Curtis J; Bao H; Hoffmayer KS
Heart Rhythm; 2018 Jun; 15(6):847-854. PubMed ID: 28987459
[TBL] [Abstract][Full Text] [Related]
17. Comparative Evaluation of Four Risk Scores for Predicting Mortality in Patients With Implantable Cardioverter-defibrillator for Primary Prevention.
Rodríguez-Mañero M; Abu Assi E; Sánchez-Gómez JM; Fernández-Armenta J; Díaz-Infante E; García-Bolao I; Benezet-Mazuecos J; Andrés Lahuerta A; Expósito-García V; Bertomeu-González V; Arce-León Á; Barrio-López MT; Peinado R; Martínez-Sande L; Arias MA
Rev Esp Cardiol (Engl Ed); 2016 Nov; 69(11):1033-1041. PubMed ID: 27491594
[TBL] [Abstract][Full Text] [Related]
18. Determinants of patient survival rate after implantation of a cardioverter-defibrillator without resynchronisation capability.
Lelakowski J; Piekarz J; Rydlewska A; Majewski J; Senderek T; Ząbek A; Małecka B
Kardiol Pol; 2012; 70(11):1099-110. PubMed ID: 23180517
[TBL] [Abstract][Full Text] [Related]
19. Risk Markers and Appropriate Implantable Defibrillator Therapy in Hypertrophic Cardiomyopathy.
Magnusson P; Gadler F; Liv P; Mörner S
Pacing Clin Electrophysiol; 2016 Mar; 39(3):291-301. PubMed ID: 26681505
[TBL] [Abstract][Full Text] [Related]
20. Implantable cardioverter-defibrillators in patients with CKD: a propensity-matched mortality analysis.
Nakhoul GN; Schold JD; Arrigain S; Harb SC; Jolly S; Wilkoff BL; Nally JV; Navaneethan SD
Clin J Am Soc Nephrol; 2015 Jul; 10(7):1119-27. PubMed ID: 26111859
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
